Fund BasicsSee More
- Fund Family Direxion Investments
- Assets Under Management 258,048,000
- Shares Outstanding, K 16,800
- 60-Month Beta 3.74
- Price/Earnings ttm 22.29
- Annual Dividend & Yield 0.08
- Most Recent Dividend 0.001
- Management Fee 0.99%
|Period||Period Low||Period High||Performance|
| || |
-1.61 (-9.68%)since 12/24/20
| || |
+5.30 (+54.53%)since 10/27/20
| || |
-48.40 (-76.32%)since 01/27/20
The solid fundamentals and a soaring stock market have resulted in huge demand for the leveraged ETFs.
Here we highlight some leveraged ETFs that were up more than 7% on the favorable update from Moderna's vaccine progress.
Last week was all about vaccine hopes and a stupendous Wall Street rally.
Wall Street spiked on Nov 9 on news that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
Wall Street put up a feeble show last week with the S&P 500, the Dow Jones and the Nasdaq Composite adding about 0.64%, 1.8% and 0.08%, respectively.
Wall Street performed decently last week with the S&P 500, the Dow Jones and the Nasdaq Composite adding about 2.5%, 3.8% and 2.5%, respectively.
The U.S. stock market extended its bull rally to start the month of June with surprisingly upbeat job data.
These leveraged ETFs gained massively in last week's Wall Street rally.
U.S. stocks continued their spectacular run to start the New Year. We highlighted eight leveraged equity ETFs that piled up double-digits gain to start 2020.
We discuss how leveraged and inverse ETFs work and what's hot this year.
|3rd Resistance Point||17.85|
|2nd Resistance Point||17.34|
|1st Resistance Point||16.37|
|1st Support Level||14.89|
|2nd Support Level||14.38|
|3rd Support Level||13.41|